This article is more than 5 years old. Information may no longer be current.
AstraZeneca to acquire Actavis' respiratory drug unit
Click Here to Manage Email Alerts
AstraZeneca has agreed to purchase Actavis’ branded respiratory business in the United States and Canada for an initial $600 million plus an additional $100 million, according to a press release.
In the transaction, AstraZeneca will own the development and commercial rights in the US and Canada to Actavis’ Tudorza Pressair (aclidinium bromide inhalation powder) and Daliresp (roflumilast) used in the treatment of COPD.
“With the addition of Tudorza and Daliresp, we will benefit from an immediate boost to revenue in our biggest market, further strengthening our growing respiratory franchise,” Paul Hudson, president of AstraZeneca US, said in the release.
The sale is subject to antitrust law clearance, and the deal is expected to close in the first quarter of the year.